Lipid nanoparticles are the small fatty bubbles that carried the COVID-19 vaccines into roughly five billion arms, and they are now the delivery vehicle of choice for a growing pipeline of mRNA therapies, gene editors, and cancer treatments. They are also a manufacturing headache. Purifying them at scale tends to involve tangential flow filtration and ultracentrifugation, processes that are slow, lossy, and expensive enough that the purification step alone can dominate the cost of goods for a clinical batch.
Amplify Dynamics, a pre-seed company founded by University of Chicago molecular engineer Gustavo, thinks there is a better way to do it with sound. The company is developing ultrafiltration hardware that uses acoustofluidics, the manipulation of particles inside microfluidic channels using ultrasonic standing waves, to separate lipid nanoparticles from process impurities [Amplify Dynamics]. The pitch to drug developers is straightforward: cleaner particles, less product loss, and a continuous process instead of a batch one.
The bet
Amplify is selling picks and shovels to the mRNA industry. The core technology was invented during Gustavo's doctoral work at the University of Chicago and is now being commercialized as purification equipment for biotech and pharma manufacturers working on lipid nanoparticle (LNP) formulations [Amplify Dynamics]. According to The Ganesha Lab, the Latin American biotech accelerator that backed the company, the goal is "delivering ultra-pure lipid nanoparticles to accelerate the development of life-saving therapies" [The Ganesha Lab].
The wedge is narrow on purpose. Rather than chase every separation problem in bioprocessing, Amplify is starting with one of the highest-value molecules in the pipeline. LNPs are notoriously sensitive to shear stress, and conventional purification can damage them or strip out the encapsulated payload, which is the entire point of the particle. An acoustic method that sorts particles by size and density without rough mechanical handling is, on paper, a good fit for a fragile, expensive product.
Why it could be big
The market tailwind is the one biotech investors have been writing memos about since 2021. Moderna, BioNTech, Pfizer, and a long tail of clinical-stage startups are all building LNP-based programs that go well beyond infectious disease vaccines, into oncology, rare disease, and gene editing. Every one of those programs needs purified material at IND-enabling scale, and most of them either run their purification in-house on legacy equipment or outsource it to contract manufacturers using the same techniques. A hardware vendor that can credibly cut purification cost or improve yield slips into a procurement conversation that the customer is already having.
Backing Amplify at this stage is The Ganesha Lab, a venture studio and accelerator focused on Latin American biotech founders, which announced its investment to support the company's purification work [The Ganesha Lab]. The funding is structured as non-equity assistance with rounds recorded in January 2024 and February 2025 [Crunchbase]. That is accelerator money, not a priced seed, which means the next twelve months are about turning a doctoral prototype into something a process development scientist at a real drug company will let near a real batch.
Back of envelope
A rough sense of why this matters at the unit-economics level. A single clinical batch of an mRNA-LNP drug product can run into the millions of dollars in raw materials and processing, and industry presentations have put downstream purification at roughly 20 to 40 percent of LNP manufacturing cost (estimated, based on public bioprocessing literature). On a $2M batch, that is $400k to $800k in purification alone. If an acoustofluidic system improves yield by even 10 percentage points (estimated), the recovered product on a single batch is worth more than most pieces of capital equipment in the suite. That is the math Amplify needs to put in front of a head of process development. It does not require revolutionary performance, just a defensible double-digit improvement on a metric the customer already tracks.
The team
Gustavo is co-founder and CEO, and is described as a molecular engineer and the inventor of the core technology, developed during his doctoral work at the University of Chicago [Amplify Dynamics]. Sebastian Saldarriaga M is also associated with the company [LinkedIn]. An inventor-led team is the right shape for a deeptech company at this stage; the harder hiring problem comes later, when Amplify needs a process engineer who has shipped GMP-adjacent equipment into a pharma customer and a commercial lead who knows the buying cycle inside large biologics organizations.
| Round | Date | Amount | Source |
|---|---|---|---|
| Non-equity assistance | Jan 2024 | Undisclosed | Crunchbase |
| Non-equity assistance | Feb 2025 | Undisclosed | Crunchbase |
The honest counterfactual
What skeptics will say: acoustofluidic separation has been an active academic field for two decades, and translating it into bioprocessing equipment that scales from microliters to the liters-per-hour throughput a commercial LNP suite needs is the part everyone underestimates. Tangential flow filtration, the incumbent, is well understood, validated, and already designed into existing facilities, which is a high switching cost regardless of how clean the new physics looks. The bull answer, supported by the company's positioning and The Ganesha Lab's thesis, is that Amplify is not asking customers to retool a whole facility. It is offering a purification module that slots into the downstream train and earns its keep on yield and product quality, the two numbers that move the cost-of-goods needle on an LNP program [The Ganesha Lab]. Whether the throughput math holds at clinical scale is the question that the next round of data will have to answer.
What to watch
The near-term milestones are technical and commercial in roughly that order. First, a peer-reviewed or customer-validated demonstration of throughput and recovery on a real LNP formulation, not a model particle. Second, a paid pilot with a CDMO or a clinical-stage mRNA developer, which is the credential that unlocks a priced seed round. Third, a hire on the bioprocess side who has sold capital equipment into pharma before. If Amplify clears those three in the next twelve to eighteen months, the non-equity assistance from The Ganesha Lab will look like a well-placed early bet on a category that the industry quietly needs.
The incumbent to beat: Repligen, the bioprocessing equipment company whose tangential flow filtration systems are the default purification choice in most LNP suites today. Amplify does not need to displace Repligen across the board. It needs to win the slot for one molecule, at one customer, on yield numbers a process engineer can defend in a tech transfer meeting.